HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Stephen J Schuster Selected Research

tisagenlecleucel

1/2022Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial.
1/2022Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.
1/2022Comparative efficacy of tisagenlecleucel and lisocabtagene maraleucel among adults with relapsed/refractory large B-cell lymphomas: an indirect treatment comparison.
1/2022Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma.
1/2022Outcomes of Tisagenlecleucel in Lymphoma Patients With Predominant Management in an Ambulatory Setting.
12/2021Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma.
10/2021Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials.
10/2021Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.
11/2020Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL.
1/2020Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Stephen J Schuster Research Topics

Disease

35Neoplasms (Cancer)
01/2022 - 11/2002
27B-Cell Lymphoma (Lymphoma, B Cell)
01/2022 - 03/2004
26Lymphoma (Lymphomas)
01/2022 - 06/2003
24Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
01/2022 - 08/2004
23B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
11/2022 - 11/2008
16Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular)
01/2022 - 06/2008
15Non-Hodgkin Lymphoma (Lymphosarcoma)
01/2022 - 06/2003
12Mantle-Cell Lymphoma (Lymphoma, Mantle Cell)
12/2019 - 09/2006
8Disease Progression
10/2021 - 09/2008
7Lymphoproliferative Disorders (Lymphoproliferative Disorder)
12/2019 - 11/2002
5Neutropenia
01/2022 - 01/2003
5Pneumonia (Pneumonitis)
04/2021 - 11/2010
5Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
12/2019 - 01/2003
5Hodgkin Disease (Hodgkin's Disease)
01/2019 - 06/2004
4Hematologic Neoplasms (Hematological Malignancy)
01/2022 - 04/2010
4Diarrhea
01/2021 - 03/2014
4Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous)
01/2021 - 03/2014
4Cytokine Release Syndrome
11/2020 - 12/2018
4Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral)
10/2020 - 01/2016
4T-Cell Lymphoma (Lymphoma, T Cell)
01/2019 - 09/2011
3Atrial Fibrillation
04/2021 - 12/2018
3Infections
04/2021 - 01/2003
3Hemorrhage
01/2020 - 01/2017
3Tumor Lysis Syndrome
01/2019 - 01/2018
3Fatigue
12/2018 - 07/2014
3Cough
11/2018 - 07/2014
3Multiple Myeloma
10/2016 - 11/2010
2Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
12/2021 - 09/2003
2Febrile Neutropenia
04/2021 - 04/2010
2Pathologic Complete Response
01/2019 - 12/2017
2Fever (Fevers)
11/2018 - 07/2014
2Nausea
11/2017 - 07/2014
2Lymphocytosis
07/2014 - 09/2003
1Pancreatic Neoplasms (Pancreatic Cancer)
12/2021
1Pneumocystis Pneumonia (Pneumocystis carinii Pneumonia)
04/2021
1Heart Arrest (Cardiac Arrest)
04/2021
1Failure to Thrive
04/2021
1Sepsis (Septicemia)
04/2021
1Cerebral Infarction
04/2021
1Burkitt Lymphoma (Burkitt's Lymphoma)
03/2021

Drug/Important Bio-Agent (IBA)

23Chimeric Antigen ReceptorsIBA
11/2022 - 01/2016
23Rituximab (Mabthera)FDA Link
01/2021 - 06/2003
20tisagenlecleucelIBA
01/2022 - 01/2016
15ibrutinibIBA
11/2022 - 07/2014
9Lenalidomide (CC 5013)FDA Link
11/2018 - 11/2010
7venetoclaxIBA
01/2022 - 01/2018
6Bexarotene (LGD1069)FDA Link
01/2021 - 08/2005
5Monoclonal AntibodiesIBA
06/2021 - 06/2003
5Phosphotransferases (Kinase)IBA
01/2021 - 09/2006
5Cyclophosphamide (Cytoxan)FDA LinkGeneric
01/2021 - 09/2003
4AntigensIBA
12/2021 - 07/2011
4axicabtagene ciloleucelIBA
10/2021 - 12/2019
4Agammaglobulinaemia Tyrosine KinaseIBA
01/2021 - 10/2018
4Methotrexate (Mexate)FDA LinkGeneric
01/2021 - 09/2003
4Doxorubicin (Adriamycin)FDA LinkGeneric
01/2021 - 09/2003
4Pharmaceutical PreparationsIBA
12/2019 - 11/2010
3Biological ProductsIBA
01/2022 - 11/2004
3Alkylating AgentsIBA
01/2022 - 03/2014
3idelalisibIBA
01/2021 - 03/2014
3CytokinesIBA
01/2019 - 09/2003
3Anti-Bacterial Agents (Antibiotics)IBA
11/2018 - 01/2003
3fludarabineIBA
06/2015 - 02/2009
3Dexamethasone (Maxidex)FDA LinkGeneric
01/2014 - 09/2003
3epratuzumabIBA
11/2008 - 12/2003
2T-Cell Antigen Receptors (T-Cell Receptor)IBA
06/2021 - 10/2020
2Prednisone (Sone)FDA LinkGeneric
01/2021 - 01/2011
2Immunoconjugates (Immunoconjugate)IBA
01/2021 - 01/2003
2Brentuximab VedotinIBA
01/2021 - 01/2021
2tocilizumab (atlizumab)FDA Link
11/2020 - 01/2020
2Proteins (Proteins, Gene)FDA Link
01/2019 - 12/2013
2ofatumumabFDA Link
12/2018 - 07/2014
2RNA (Ribonucleic Acid)IBA
01/2018 - 08/2007
2Immunoglobulin M (IgM)IBA
12/2017 - 03/2004
2Immunoglobulin G (IgG)IBA
12/2017 - 12/2003
2NivolumabIBA
10/2016 - 01/2015
2Anaplastic Lymphoma KinaseIBA
01/2016 - 12/2013
2Membrane Proteins (Integral Membrane Proteins)IBA
03/2014 - 08/2007
2Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA
07/2011 - 09/2008
2Vincristine (Oncovin)FDA LinkGeneric
01/2011 - 09/2003
2Lactic Acid (Lactate)FDA LinkGeneric
01/2011 - 04/2010
2ORALIT (ORS)IBA
07/2009 - 08/2004
2RetinoidsIBA
10/2008 - 08/2005
1pembrolizumabIBA
01/2022
1MesothelinIBA
12/2021
1Single-Chain AntibodiesIBA
06/2021
1Bispecific AntibodiesIBA
06/2021
1blinatumomabIBA
06/2021
1ublituximabIBA
04/2021
1Immune Checkpoint ProteinsIBA
03/2021

Therapy/Procedure

54Therapeutics
01/2022 - 01/2003
14Drug Therapy (Chemotherapy)
10/2021 - 01/2003
7Stem Cell Transplantation
10/2021 - 10/2013
4Immunotherapy
01/2021 - 09/2008
4Transplantation
01/2020 - 01/2003
4Organ Transplantation
06/2013 - 08/2005
4Radioimmunotherapy
06/2008 - 06/2003
3Radiotherapy
01/2020 - 09/2008
2Retreatment
01/2022 - 01/2016
2Cell Transplantation
12/2019 - 09/2003
2Aftercare (After-Treatment)
09/2005 - 01/2005